Serum Sclerostin But Not DKK-1 Correlated with Central Arterial Stiffness in End Stage Renal Disease Patients

Chun-Feng Wu, Jia-Sian Hou, Chih-Hsien Wang, Yu-Li Lin, Yu-Hsien Lai, Chiu-Huang Kuo, Hung-Hsiang Liou, Jen-Pi Tsai and Bang-Gee Hsu
Additional contact information
Chun-Feng Wu: Division of Metabolism and Endocrinology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan
Jia-Sian Hou: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
Chih-Hsien Wang: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
Yu-Li Lin: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
Yu-Hsien Lai: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
Chiu-Huang Kuo: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan
Hung-Hsiang Liou: Division of Nephrology, Department of Medicine, Hsin-Jen Hospital, New Taipei City 24243, Taiwan
Jen-Pi Tsai: School of Medicine, Tzu-Chi University, Hualien 97004, Taiwan
Bang-Gee Hsu: Division of Nephrology, Buddhist Tzu-Chi General Hospital, Hualien 97004, Taiwan

IJERPH, 2020, vol. 17, issue 4, 1-13

Abstract: Sclerostin and dickkopf-1 (DKK1) played a role in the development of cardiovascular diseases and arterial stiffness in chronic kidney disease (CKD) patients but with controversial results of patients in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). This study aimed to examine the association between the mode of dialysis or the values of sclerostin or DKK1 and carotid-femoral pulse wave velocity (cfPWV) in ESRD patients. There were 122 HD and 72 PD patients enrolled in this study. By a validated tonometry system, cfPWV was measured and then segregated patients into values of >10 m/s as the high central arterial stiffness (AS) group and values ≤ 10 m/s as the control group. Serum levels of sclerostin and DKK1 were measured using a commercial enzyme-linked immunosorbent assay kit. Possible risk factors for the development of AS were analyzed by logistic regression analysis. There were 21 (29.2%) of PD and 53 (43.4%) of HD in the high AS group. Compared to patients in the control group, those in the high AS group were older, had more comorbidities, had higher systolic blood pressure, and had higher serum levels of fasting glucose, C-reactive protein, and sclerostin. Levels of sclerostin (adjusted OR 1.012, 95% CI. 1.006–1.017, p = 0.0001) was found to be an independent predictor of high AS in ESRD patients by multivariate logistic regression analysis. Furthermore, receiver operating characteristic curve analysis showed the optimal cut-off values of sclerostin for predicting AS was 208.64 pmol/L (Area under the curve 0.673, 95% CI: 0.603–0.739, p < 0.001). This study showed that serum levels of sclerostin, but not DKK1 or mode of dialysis, to be a predictor for high central AS in ESRD patients.

Keywords: arterial stiffness; carotid–femoral pulse wave velocity; end-stage renal disease; Dickkopf-1; hemodialysis; peritoneal dialysis; aclerostin (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/4/1230/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/4/1230/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:4:p:1230-:d:320573

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().